← Back
Zevra Therapeutics
ZVRA · listed on Nasdaq · worth $610.47 million
$10.28
−0.77% on Oct 30
No insider bought Zevra Therapeutics stock in the last year. They sold it 12 times, $2.5 million in all.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
53.9M shares
91% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, six insiders sold Zevra Therapeutics stock and none bought. Two of the 12 sales are marked on the filing as planned in advance; most by company executives. The biggest seller was Neil F. McFarlane, President and CEO.
Planned sales
Form 144 notices filed for Zevra Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
CEO Neil F. McFarlane filed to sell 20,000 shares on 12 Oct; sold 20,000 by 12 Oct10b5-1 plan adopted 25 Mar 2026 · Notice on SEC.gov
Executive Rahsaan Thompson filed to sell 42,666 shares on 14 Aug; sold 42,666 by 14 Aug10b5-1 plan adopted 15 May 2026 · Notice on SEC.gov
Director John B. Bode filed to sell 10,516 shares on 8 Jul; no sale reported in the three months afterNotice on SEC.gov
Big investors
People and funds that reported owning 5% or more of Zevra Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateWoodline Partners LP8.1%Aug 14
Filed by someone who owns 5% or more and does not plan to influence the company. · updateFMR LLC8.3%Aug 6
Filed by someone who owns 5% or more and does not plan to influence the company.Vanguard Capital Management LLC5.1%Jul 31
All reports
Every insider trade and SEC report we hold for Zevra Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Oct 13SoldNeil F. McFarlaneOct 13 · Traded Oct 12 · President and CEO · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.20,000 @ $11.25$224.9K
Aug 17SoldRahsaan ThompsonAug 17 · Traded Aug 14 · Chief Legal & Compliance · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.42,666 @ $11.13$474.8K
12 more with Pro →Analysts, earnings and news
Analysts' price target
$25.00 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
4 of 4 quarters above
Q2 '26$0.25 a share+$0.07
Q1 '26$0.18 a share+$0.10
Q4 '25$0.19 a share+$0.15
Q3 '25−$0.01 a share+$0.01